摘要
JARID1B(jumonji AT rich interactive domain 1B)有PLU-1/JARID1B、RBP2-H1/JARID1B和RBBP2H1A/JARID1B三种剪接体;有五种保守的结构域:JmjC、JmjN、ARID、PHD和ZF;通过羟基化作用使组蛋白赖氨酸H3K4me1/2/3去甲基而参与转录调节,参与细胞周期调控、细胞分化和细胞系基因表达的调控;在不同的组织、肿瘤及肿瘤细胞系中表达不同,与癌症的发生和发展相关,是潜在的抗癌药物的作用靶点。
Histone demethylase JARID1B (jumonji, AT rich interactive domain 1B) has three splicing variants: PLU-1/ JARID1B, RBP2-HI/JARID1B and RBBP2H1A/JARIDIB. It has five conservative domains: JmjC, JmjN, ARID, PHD and ZF. It demethylates H3K4me1/2/3 and represses transcription. Its expression is different in different tissues, tumors, and tumor cell lines. JARID1B controls cell cycle, differentiation and cell lineage and relates to some cancers. Thus, JARID1B has potential target sites of anti-cancer drugs.
出处
《生命的化学》
CAS
CSCD
北大核心
2009年第4期524-528,共5页
Chemistry of Life